{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-26-000049","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2026-08-12T11:33:59+00:00","discovered_at":"2026-08-12T11:35:00.282210+00:00","generated_at":"2026-08-12T11:35:06.014115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Altimmune Q2 net loss $22.8M; initiates Phase 3 MASH trial, positive AUD data","bullets":["Net loss $22.8M ($0.12/share) vs $22.1M ($0.27/share) in Q2 2025; R&D $18.7M, G&A $7.6M.","Cash and investments $519M as of June 30, 2026; gross proceeds $225M from April 2026 offering.","Initiated global PERFORMA Phase 3 MASH trial; 52-week data expected 2029; pemvidutide granted FDA Breakthrough Therapy.","Positive topline RECLAIM Phase 2 AUD: significant reduction in heavy drinking days; Fast Track designation.","Completed enrollment in RESTORE Phase 2 ALD trial; topline data expected H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-26-000049","json":"https://secwatch.observer/filing/0001326190-26-000049.json","markdown":"https://secwatch.observer/filing/0001326190-26-000049.md","text":"https://secwatch.observer/filing/0001326190-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/0001326190-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/alt-20260812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T11:35:06.014115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}